WuXi AppTec Receives 2017 Global Integrated Drug R&D Services Competitive Strategy Innovation & Lead

WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform, today announced that it has been awarded the 2017 Frost & Sullivan Global Integrated Drug R&D Services Competitive Strategy Innovation & Leadership Award.

The award is part of the Frost & Sullivan Best Practices Award series, which recognizes best-in-class companies that have demonstrated excellence in their respective industries. WuXi has been recognized for its strong growth performance, alignment with market needs, breadth of products and solutions, and strategy and achievements.

"WuXi AppTec is a prominent participant in the integrated drug R&D services global market. The company's competitive advantage is attributed to its strong drug development services, capability in providing a wide range of analytical testing solutions and personalized offerings" said Sanjeev Kumar, analyst from Frost & Sullivan Transformational Health Practice. "Amid an aggressive market, WuXi AppTec has always been ahead of its competitors, excelling in quality and timely project deliveries. WuXi AppTec's operational capabilities are exceptional, being committed toward providing best-in-class services to its clients." 

"We thank Frost & Sullivan for recognizing WuXi's role in helping our partners develop innovative products through our open-access capability and technology platform," said Dr. Ge Li, chairman and CEO of WuXi AppTec. "We also thank our customers and collaborative partners for their trust and support. We will continue to strengthen our platform to enable our collaborative partners, and to fulfill WuXi's dream that every drug can be made and every disease can be treated."

About WuXi AppTec
WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, and medical device testing, WuXi platform is enabling over 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated." Please visit http://www.wuxiapptec.com